| Dr
Reddy's gets US FDA nod for marketing ciprofloxacin
8 November 2007
Mumbai:
Dr Reddy's Laboratories Ltd has received approval from the US Food and Drug Administration
to market its anti-infective ciprofloxacin extended-release tablets. The
drug maker also received approval to market rivastigmine tartrate capsules, a
 generic
variant of Novartis' Exelon capsules, indicated in the treatment of mild dementia
associated with Alzheimer's disease and Parkinson's disease, USFDA said in statement
in its website. Other
reports on Dr. Reddy's Labs Other
reports on Pharmaceuticals General
reports on Marketing
| 
